HPV's Role in Nasal and Sinus Cancer Revealed: Molecular Mapping and New Treatments

What Is Sinonasal Cancer?

Sinonasal cancers arise in the nasal cavity and paranasal sinuses , particularly the maxillary, ethmoid, frontal and sphenoid sinuses. Most are sinonasal squamous cell carcinomas (SNSCC).

• Sinonasal tumors account for only 3–5% of all head-and-neck cancers .

• However, they are highly heterogeneous, genetically complex and often diagnosed late , resulting in poor prognosis.

Although squamous cell carcinomas here resemble oropharyngeal or laryngeal cancers histologically, their molecular features and risk factors differ. HPV's role has only recently begun to be understood.

🔍 A Notable Recent Nature Study

Approximately 25% of these tumors were known to be associated with human papillomavirus (HPV) . Whether HPV was a true driver or merely a passenger remained uncertain. Published on 11 June 2025 in Nature Communications, this large genomic analysis clarifies HPV's role and the molecular differences between HPV-positive and HPV-negative tumors, identifying promising targets for personalized treatment.

🧬 HPV-Positive and HPV-Negative Sinonasal Cancers: Different Genetic Routes and Strategies

Study Design:

Researchers performed detailed genomic and transcriptomic analysis of 35 SNSCC tumor samples from patients diagnosed with sinonasal squamous cell carcinoma. Samples were grouped as HPV-positive (n=18) and HPV-negative (n=17) . HPV status was confirmed through multiple methods: RNA in situ hybridization, p16 immunohistochemistry and viral DNA sequencing .

Techniques included:

• Whole-exome sequencing (WES): Identifying mutations and variant signatures.

• RNA sequencing (RNA-seq): Defining gene expression patterns and pathway activation.

• Copy number variation (CNV) analysis: Detecting genomic instability.

• Viral DNA integration mapping: Custom algorithms identified where and how HPV integrates into the human genome.

• The first dedicated cell line from HPV-positive disease, NCI-197 , was also developed for targeted treatment testing.

These methods revealed genetic and functional differences in SNSCC according to HPV status.

📌 Molecular Signature of HPV+ Tumors:

• No TP53 mutations (because HPV E6 suppresses TP53).

• PIK3CA (E542K/E545K) and FGFR3 (S249C) hotspot mutations were common (80% and 66%).

• APOBEC mutagenesis predominated: COSMIC signature #13 was enriched in HPV+ tumors (p=0.017).

• Viral DNA integrationoccurred near fragile genomic regions, particularly TP63 and KLF5.

📌 Molecular Signature of HPV– Tumors:

• TP53 mutations in 70% of tumors.

• Other Common Mutations: NOTCH1, KRAS, CDKN2A, FAT4.

• No smoking-associated mutational signature was found, but classical RAS/PI3K and MYC activation was prominent.

🎯 Findings to Guide Treatment: Which Target for Which Patient?

✅ In HPV+ Patients:

• PI3K + YAP/TAZ pathways were active.

• In the NCI-197 cell line developed for the study, the PI3K inhibitor alpelisib and the YAP/TAZ inhibitor verteporfin were tested in vitro, suppressing colony formation by up to 90%.

• The combination showed synergy (Loewe synergy score >10).

✅ In HPV– Patients:

• MYC, RAS, PI3K parallel pathway activation predominated.

• Combinations of MYC-suppressing agents and pan-PI3K/RAS inhibitors may be potential treatments.

📉 Mutations Associated with Survival

• KMT2D mutations in HPV+ patientswere associated with significantly poorer survival (p=0.0377).

• FGFR3 mutations also adversely affected survival (p=0.0516).

• TP53 mutations in HPV– patientswere associated, as expected, with substantially worse survival (p=0.0093).

🧪 New Discoveries: Uncommon Mutations

Mutations common in HPV+ SNSCC but rare in other head-and-neck or cervical cancers included:

• UBXN11 (c.1464_1541): May indirectly affect the p53 pathway.

• AP3S1 (P158L): May create an immunosuppressive microenvironment.

• MT-ND4 and MT-ND5: May facilitate metastasis through mitochondrial pathways.

These mutations could be specific biomarkers for HPV-associated sinonasal cancer .

🧭 Recommendations for Clinical Practice

• In SNSCC, HPV RNA in situ hybridization and p16 staining should be used together.

• p16-negative but HPV RNA-positive tumors resemble HPV-negative tumors molecularly and behave differently, requiring special diagnostic attention.

• SCCs arising in the nasolacrimal systemshould be classified with HPV+ SNSCC because of molecular similarities.

🧩 Conclusion: Molecular Maps, New Directions

Beyond revealing biological differences among SNSCC subtypes, this study marks a milestone toward personalized oncology. Particularly in HPV+ patients, inhibiting targets such as PI3K and YAP/TAZ could form the basis of future clinical trials.